Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

Article Details

Citation
Copy to clipboard

Lakehal F, Wurden CJ, Kalhorn TF, Levy RH

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

Epilepsy Res. 2002 Dec;52(2):79-83.

PubMed ID
12458024 [ View in PubMed
]
Abstract

Multiple studies suggest that phenytoin concentrations increase with CBZ co-medication. This study evaluated the hypothesis that CBZ and/or its major metabolite (CBZE) inhibit CYP2C19-mediated phenytoin metabolism using human liver microsomes and cDNA-expressed CYP2C19. Oxcarbazepine (OXC), and its 10-monohydroxy metabolite (MHD) were also evaluated. CBZ and MHD inhibited CYP2C19-mediated phenytoin metabolism at therapeutic concentrations. Thus, administration of CBZ and OXC with CYP2C19 substrates with narrow therapeutic ranges should be done cautiously.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
CarbamazepineCytochrome P450 2C19ProteinHumans
Unknown
Inhibitor
Inducer
Details
Drug Interactions
DrugsInteraction
Integrate drug-drug
interactions in your software
Binimetinib
Rifabutin		The metabolism of Binimetinib can be increased when combined with Rifabutin.
Binimetinib
Enzalutamide		The metabolism of Binimetinib can be increased when combined with Enzalutamide.
Imipramine
Rifabutin		The metabolism of Imipramine can be increased when combined with Rifabutin.
Thiopental
Rifabutin		The metabolism of Thiopental can be increased when combined with Rifabutin.
Thiopental
Phenytoin		The metabolism of Thiopental can be increased when combined with Phenytoin.